Health Care/Hospital

New Lunit Study Demonstrates Universal AI Model for Analysis of Immunohistochemistry Images

Research in npj Precision Oncology highlights multi-cohort training approach and accurate analysis of unseen immunohistochemistry data SEOUL, South Korea, Dec. 12, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, toda...

2024-12-12 22:08 1638

Bota Bio debuted the 2024 FiE and launched its subsidiary HeliaGenesis, focusing on food and nutrition industries

SAN FRANCISCO and HANGZHOU, China, Dec. 12, 2024 /PRNewswire/ -- The 31st Food Ingredients Europe (referred to as FiE) concluded successfully fromNovember 19th to 21st, 2024, in Frankfurt, Germany. The event brought together over 1,500 ingredient manufacturers and more than 25,000 professional bu...

2024-12-12 22:00 1575

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

- A Milestone in Preventive Healthcare and Technological Innovation in Long An TÂN AN CITY, Vietnam, Dec. 12, 2024 /PRNewswire/ -- Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to developVietnam's first AI x ESG Hospital, marking a significant milestone...

2024-12-12 21:23 1927

CureGene Received Clinical Trial Approval in China for CG-0255 for Injection - A Novel Antiplatelet Therapy

SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- CureGene Pharmaceutical ("CureGene"), a biotechnology company dedicated to innovative treatments for critical unmet medical needs in cardio-cerebrovascular and antiviral disease, proudly announces the approval of its Clinical Trial Application by theChina's...

2024-12-12 21:00 1315

Porton Pharma Solutions and Aojin Life Sciences Announce Strategic Collaboration to Advance XDC Conjugate Drugs for Dual IND Filings in China and the U.S.

CHONGQING, China, Dec. 12, 2024 /PRNewswire/ -- Recently, Porton Pharma Solutions Ltd. ("Porton") announced a strategic partnership with Aojin Life Sciences (Yixing) Co., Ltd. ("Aojin Life Sciences"). Porton will provide comprehensi...

2024-12-12 21:00 1391

SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate

* SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials inAustralia in February 2025, with interim results expected by 2026. * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI. * SK bioscience will respond to...

2024-12-12 21:00 1641

Xinhua Silk Road: Pien Tze Huang boosts TCM globalization

BEIJING, Dec. 12, 2024 /PRNewswire/ -- Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd., aFujian-based traditional Chinese medicine (TCM) company, has been striving to expand its overseas markets, enhancing the influence of TCM in regions such asSoutheast Asia and Europe. Committed to deepening...

2024-12-12 20:43 1789

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

* ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast cancer withESR1 mutations, aiming to delay disease progression. * The study was presented by the Menarini Group and MEDSIR at the San Ant...

2024-12-12 18:07 1509

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

New collaboration delivers cashless services, as well as access to expedited appointments for outpatient cancer treatment services and independent cancer medical consultation, ensuring comprehensive and convenient protection for  customers HONG KONG, Dec. 12, 2024 /PRNewswire/ -- Manulife Hong Ko...

2024-12-12 17:30 1885

WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection

* Leading Green CRDMO Driven by Innovation for a Healthier Future * Offering End-to-end Green Biologics Solutions for the Entire Industry SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organizati...

2024-12-12 16:30 1390

KIND Presents Preclinical Results of AND017 in Animal Models of Sickle Cell Disease (SCD), Myelodysplastic Syndromes (MDS), and β-Thalassemia at the 66th American Society of Hematology Meeting and Exposition and Announces FDA Authorization of Investigational New Drug (IND) Application for AND017 for Clinical Trial in Sickle Cell Disease (SCD)

SAN FRANCISCO, Dec. 12, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that preclinical...

2024-12-12 16:25 1245

Waterdrop Inc. Announces Third Quarter 2024 Unaudited Financial Results, Net profit rises 152.6% year-on-year

BEIJING, Dec. 12, 2024 /PRNewswire/ -- On December 11, 2024, Waterdrop Inc. (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, unveiled its unaudited financial results for the third quarter of 2024 endedSeptember 30, 2024. Duri...

2024-12-12 16:13 2138

RSNA 2024 Spotlight: Careverse Leads the New Trend in Medical AI

CHICAGO, Dec. 12, 2024 /PRNewswire/ -- From December 1st to 5th, 2024, RSNA 2024—the largest and most future-oriented top medical event in the global radiology community, was held inChicago. At this conference, Careverse officially made its debut, exhibiting in the AI Showcase area, sharing its ...

2024-12-12 16:04 944

2024 Design Intelligence Award Held at China Academy of Art, Hangzhou, China

HANGZHOU, China, Dec. 12, 2024 /PRNewswire/ -- The ceremony for the 2024 Design Intelligence Award (DIA) took place onDecember 6 at the Liangzhu Campus of China Academy of Art (CAA). The Fourier General-Purpose Humanoid Robot GR-1 clinched the Grand Award, the highest prize of DIA. Gold Awards we...

2024-12-12 14:17 1161

CBC Group R-Bridge Healthcare Fund Announces up to US$50 Million Financing for Human Investments Ltd. to Fund Motiva® Market Expansion

* Non-dilutive growth financing of up to US$50 million, with a synthetic royalty feature, and availability linked to achievement of certain sales milestones * Proceeds from the financing will fund Human Investments Ltd.'s expansion of Motiva® devices inAsia * Transaction highlights R-Bridge...

2024-12-12 14:14 2855

Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients

SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription of VELSIP...

2024-12-12 11:48 1780

Laekna Announces Poster Presentation on Internally Discovered Selective PI3Kα Inhibitor at SABCS 2024

LOS ANGELES, Dec. 11, 2024 /PRNewswire/ -- Laekna (2105.HK) today announced that the company will present an internally discovered preclinical candidate at the 2024 San Antonio Breast Cancer Symposium (SABCS) onDecember 13, 2024. The presentation will feature preclinical characterization of LAE11...

2024-12-12 08:30 1130

QNET Stands in Solidarity with Cambodia and the World for a Mine-Free Future

HONG KONG, Dec. 12, 2024 /PRNewswire/ -- QNET, a global leader in direct selling and lifestyle products, proudly sponsored the recently concluded'March for aMine-Free World' in Siem Reap, Cambodia. This impactful event, hosted in collaboration with the Cambodian Mine Action and Victim Assistance ...

2024-12-12 01:34 2727

THERME GROUP ACQUIRES THERME ERDING AND SECURES €320 MILLION FINANCING, TO CREATE THE WORLD'S LARGEST WELLBEING INFRASTRUCTURE PLATFORM

The Acquisition of Europe's Largest Wellbeing Destination, Backed by One of the Industry's Largest Single-Asset Financings LONDON, Dec. 12, 2024 /PRNewswire/ -- Therme Group announces the acquisition ofTherme Erding, the largest wellbeing destination globally located near Munich inGermany. With ...

2024-12-12 00:03 2614

GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz™

** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the Emergency Room ** *Multinational Phase 3 Clinical Trial protocols confirmed and initiated with leading global stroke research centers * SEOUL, South Korea, Dec. 11, ...

2024-12-11 23:15 1917
1 ... 3456789 ... 855